Fatty Acid Supplement for Dermatomyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This study tests whether taking a fatty acid supplement (omega-3) for 6 months can help reduce disease activity in people with dermatomyositis. Participants will also receive dietary coaching and have regular check-ups at the NIH to monitor their progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old and have been diagnosed with dermatomyositis or juvenile dermatomyositis.
- You need to be willing to follow a healthy diet plan and have regular online coaching sessions (about 10 sessions over 6 months).
- You must be able to take 4 study pills twice a day for 6 months and complete all study visits at the NIH Clinical Center in Bethesda, Maryland.
- You must be able to wear a small activity tracker (like a watch) for 7 days, twice during the study, and provide blood, stool, urine samples, and have imaging tests done.
- You need to have access to a computer or smartphone with internet and an active email address for online forms and telehealth visits.
- You should not have significant medical conditions (like severe heart or kidney disease, certain infections, or recent cancer) that might make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well skin symptoms improve in adults with cutaneous dermatomyositis by using a specific skin-scoring tool. The results may help doctors better measure treatment response and guide care.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This trial tests an investigational drug called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rashes. The goal is to see if the drug can help control the disease.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
Hear when a new Dermatomyositis (DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.